A new study uncovers how fibroblasts resist being converted into functional heart cells, pinpointing sulfotransferase signaling as a molecular brake on therapeutic cardiac reprogramming. Published in Nature Communications in 2026, the work links a specific biochemical pathway to the persistence of fibroblast identity, offering a fresh target for regenerative strategies.
Fibroblasts are abundant in injured myocardium and typically form scar-like structures that can limit contractile recovery. While gene- and factor-based reprogramming approaches aim to redirect these cells toward cardiomyocyte-like states, success has been inconsistent, suggesting that stable “cell identity” programs are actively maintained.
Romero and colleagues report that sulfotransferase-driven signaling helps fibroblasts lock in their fate. By sustaining key identity-associated transcriptional and signaling outputs, the pathway appears to create an internal environment that makes conversion inefficient, even when reprogramming cues are supplied.
The authors combine perturbation experiments with signaling analyses to test causality. When sulfotransferase activity or its downstream signaling is impaired, fibroblasts show reduced resistance to fate change, with reprogramming protocols producing stronger cardiomyocyte-associated gene programs.
Mechanistically, the team focuses on how sulfotransferases modify cellular components—processes that can tune receptor interactions, extracellular matrix behavior, and intracellular signal propagation. These chemical modifications collectively shape the reprogramming landscape, influencing whether cells respond to therapeutic instructions or revert to—or maintain—the fibroblast state.
The study also suggests that sulfotransferase signaling acts not merely as a marker of fibroblast identity, but as an antagonistic force during reprogramming. In this view, fibroblasts employ sulfation-dependent pathways to defend their phenotype against lineage switching.
Importantly for translation, the findings imply that combination therapies may be necessary. Effective reprogramming could require both delivery of cardiogenic factors and concurrent inhibition of pro-fibroblast sulfotransferase signaling.
Overall, the research reframes cardiac reprogramming resistance as a biochemical defense system. By identifying sulfotransferase signaling as a driver of fibroblast stability, it opens a path toward more reliable regenerative outcomes.
